Evaluation of Host Gene Methylation as a Triage Test for HPV-Positive Women-A Cohort Study.
Journal
Journal of lower genital tract disease
ISSN: 1526-0976
Titre abrégé: J Low Genit Tract Dis
Pays: United States
ID NLM: 9704963
Informations de publication
Date de publication:
26 Jul 2024
26 Jul 2024
Historique:
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
aheadofprint
Résumé
This study was designed to evaluate the performance of a host gene methylation marker panel (ASTN1, DLX1, ITGA4, RXFP3, SOX17, and ZNF671) in the triage of human papillomavirus (HPV)-positive women, its possible impact in a cervical cancer screening program, and the possible influence of the variation of the rate of HPV16/18 in its performance. Cohort study in which consecutive women referred for colposcopy in an organized cervical cancer screening program had repeated HPV testing, colposcopy, and biopsies. The women that remained HPV positive at the time of colposcopy were tested with the panel of DNA methylation markers. The performance of the test was evaluated and compared to standard practice. The study test had a sensitivity and specificity for cervical intraepithelial neoplasia (CIN) 2+ of 60.8% (49.1-71.6%) and 88.4% (83.2-92.5%), respectively. For CIN3+, it was of 78.0% (64.0-88.5%) and 86.0% (80.8-90.2%), respectively.The rate and level of methylation positively correlated with the severity of disease. The use of methylation reduces the referral for colposcopy to 25.5%, while detecting 78.0% of the CIN3+ cases. Referral of all HPV16/18-positive cases and triage of the other high-risk HPV-positive cases with methylation, detects 90.0% of the cases of CIN3+, while reducing the number of referrals to 43.2%.The variation in the rate of HPV16/18 does not relevantly affect the performance of the methylation panel. The studied methylation panel has a high sensitivity and specificity for CIN3+ and reduces the rate of referrals for colposcopy, without relevant variation according to the rate of HPV16/18.
Identifiants
pubmed: 39058311
doi: 10.1097/LGT.0000000000000830
pii: 00128360-990000000-00129
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the ASCCP.
Déclaration de conflit d'intérêts
Conflicts of interest: PVB received speaker fees from Seegene.
Références
Marcus JZ, Cason P, Downs LS Jr., et al. The ASCCP Cervical Cancer Screening Task Force Endorsement and Opinion on the American Cancer Society Updated Cervical Cancer Screening Guidelines. J Low Genit Tract Dis 2021;25:187–91.
Rintala S, Dahlstrom KR, Franco EL, et al. A synthesis of evidence for cancer-specific screening interventions: a preventive medicine golden jubilee review. Prev Med 2023;167:107395.
von Karsa L, Arbyn M, De Vuyst H, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res 2015;1:22–31.
Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis 2015;19:91–6.
Kyrgiou M, Athanasiou A, Kalliala IEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev 2017;11:Cd012847.
Stanczuk GA, Baxter GJ, Currie H, et al. Defining optimal triage strategies for hrHPV screen-positive women—an evaluation of HPV 16/18 genotyping, cytology, and p16/Ki-67 cytoimmunochemistry. Cancer Epidemiol Biomarkers Prev 2017;26:1629–35.
Arbyn M, Rezhake R, Yuill S, et al. Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence. Br J Cancer 2020;122:1577–9.
de Waard J, Bhattacharya A, de Boer MT, et al. Identification of a methylation panel as an alternative triage to detect CIN3+ in hrHPV-positive self-samples from the population-based cervical cancer screening programme. Clin Epigenetics 2023;15:103.
Richardson LA, El-Zein M, Ramanakumar AV, et al. HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status. Cancer Cytopathol 2015;123:745–54.
Rauf SA, Zehra SA, Shah HH. Beyond P16/Ki67 dual-stain cytology: exploring alternative biomarkers for diagnosing cervical cancer and its precursors. BJOG 2023;131:115–6.
Dovnik A, Poljak M. The role of methylation of host and/or human papillomavirus (HPV) DNA in management of cervical intraepithelial neoplasia grade 2 (CIN2) lesions. Int J Mol Sci 2023;24:6479.
Schmitz M, Eichelkraut K, Schmidt D, et al. Performance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages. BMC Cancer 2018;18:1197.
Bowden SJ, Kalliala I, Veroniki AA, et al. The use of human papillomavirus DNA methylation in cervical intraepithelial neoplasia: a systematic review and meta-analysis. EBioMedicine 2019;50:246–59.
Rosário A, Sousa A, Marinho-Dias J, et al. Impact of high-risk human papillomavirus genotyping in cervical disease in the northern region of Portugal: real-world data from regional cervical cancer screening program. J Med Virol 2023;95:e28414.
Akoglu H. User's guide to sample size estimation in diagnostic accuracy studies. Turk J Emerg Med 2022;22:177–85.
Schmitz M, Wunsch K, Hoyer H, et al. Performance of a methylation specific real-time PCR assay as a triage test for HPV-positive women. Clin Epigenetics 2017;9:118.
Saldanha C, Vieira-Baptista P, Costa M, et al. Impact of a high coverage vaccination rate on human papillomavirus infection prevalence in young women: a cross-sectional study. J Low Genit Tract Dis 2020;24:363–6.
Dippmann C, Schmitz M, Wunsch K, et al. Triage of hrHPV-positive women: comparison of two commercial methylation-specific PCR assays. Clin Epigenetics 2020;12:171.
Vieira-Baptista P, Lyra J, Melo C, et al. Immediate loop electrode excisional procedure for high-grade cervical cytology: one size fits all? J Low Genit Tract Dis 2019;23:84.
Del Vecchio NJ, Beaber EF, Garcia MP, et al. Provider- and facility-level variation in precancerous cervical biopsy diagnoses. J Low Genit Tract Dis 2023;27:113–9.
Lycke KD, Kahlert J, Damgaard RK, et al. Clinical course of cervical intraepithelial neoplasia grade 2: a population based study. Am J Obstet Gynecol 2023;229:656.e1–656.e15.
Austin RM, Onisko A, Zhao C. Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk? J Am Soc Cytopathol 2020;9:602–6.
Bierkens M, Hesselink AT, Meijer CJ, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer 2013;133:1293–9.
Gök M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010;340:c1040.
Luttmer R, De Strooper LM, Dijkstra MG, et al. FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. Br J Cancer 2016;115:579–87.
Hillyar CR, Kanabar SS, Pufal KR, et al. A systematic review and meta-analysis of the diagnostic effectiveness of human papillomavirus methylation biomarkers for detection of cervical cancer. Epigenomics 2022;14:1055–72.
Klischke L, von Ehr J, Kohls F, et al. Performance of a six-methylation-marker assay on self-collected cervical samples - a feasibility study. J Virol Methods 2021;295:114219.
Chu MM, Cheung CS, Ngu SF, et al. The value of four-quadrant cervical biopsy in women with different colposcopic impressions. Diagnostics (Basel) 2023;13:2384.